BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center researchers plan to test a novel adoptive cell immunotherapy platform in phase I/II clinical trials after seeing promising results in preclinical studies.

Roswell Park Cancer Institute researchers have identified a gene that influences metastasis in prostate cancer, and may help clinicians to identify aggressive prostate tumors before they progress and spread to other organs. 

John Krolewski, MD, PhD, has been appointed as Chair of the Department of Cancer Genetics and Genomics and Co-Leader of the Cancer Center Support Grant (CCSG) Genetics and Genomics Program at Roswell Park Comprehensive Cancer Center.

Tamoxifen is widely used for the treatment of women diagnosed with certain types of early and advanced breast cancers, but not all patients will benefit from it. A team from Roswell Park Cancer Institute and Northwestern University examined the mechanisms behind tamoxifen resistance.

An accomplished urologic oncologist and longtime senior leader at Roswell Park Comprehensive Cancer Center was surprised with an incredible distinction at the National Comprehensive Cancer Network (NCCN) Annual Conference last week in Florida. James Mohler, MD, Associate Director and Senior Vice President for Translational Research, Chair of the Department of Urology, and Professor of Oncology at Roswell Park, received the 2017 Rodger Winn Award at the NCCN 22nd Annual Conference in Orlando, Fla.